Thursday, Ocular Therapeutix, Inc. (OCUL) announced positive findings from the Phase 1 HELIOS study, which assessed Axpaxli against a sham control among patients with moderately severe to severe non-proliferative diabetic retinopathy or NPDR but without diabetic macular edema.
The company reported that Axpaxli was generally well-tolerated, with no observed inflammation.
In the Axpaxli group, 6 out of 13 patients experienced a 1 or 2-step enhancement in the Diabetic Retinopathy Severity Scale after 40 weeks. Additionally, none of the patients in the Axpaxli group showed a deterioration, unlike the 12.5% noted in the control group at the same time point.
The company highlighted that a single Axpaxli injection resulted in sustained DRSS improvement for up to 40 weeks.
Based on the encouraging HELIOS results, the company intends to proceed directly to a Phase 3 study involving Axpaxli for NPDR patients, pending FDA discussions.
Ocular stated that it plans to share the study outcomes at an upcoming meeting.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.